

# Stanford

---



## Andrew Zolopa

Professor of Medicine (Infectious Diseases) at the Stanford University Medical Center,  
Emeritus

Medicine - Infectious Diseases

### Bio

---

#### ACADEMIC APPOINTMENTS

- Emeritus Faculty - University Medical Line, Medicine - Infectious Diseases

#### ADMINISTRATIVE APPOINTMENTS

- Acting Chief of Infectious Diseases, Stanford University, School of Medicine, (2008-2010)

#### COMMUNITY AND INTERNATIONAL WORK

- Rwanda/Stanford HIV Mentoring Program, Rwanda Africa

#### LINKS

- Stanford AIDS Clinical Trials Unit: <http://actu.stanford.edu/>

### Research & Scholarship

---

#### CURRENT RESEARCH AND SCHOLARLY INTERESTS

Dr. Zolopa's research applies a variety of clinical epidemiologic methods in an effort to optimize antiretroviral therapy and understand the impact of drug resistance on response to ARV. Areas of focus include the clinical application of resistance testing in optimizing antiretroviral therapy, clinical cohorts, trials of antiretroviral therapies and population-based epidemiologic evaluation of HIV resistance and efficacy of ARV therapy. As the Principal Investigator of Stanford's NIH sponsored AIDS Clinical Trials Unit Dr. Zolopa is engaged in a variety of clinical trials focused on the optimization of ART both in the US and in income limited settings.

More recently studies focused on premature aging in HIV infected populations. This work will involve detailed immunologic evaluations and evaluation of end organ complications including heart disease, bone disease, renal disease and neuro-cognitive decline.

Finally, Dr. Zolopa is involved in HIV research in collaboration with the Rwandan Ministry of Health in Africa.

#### CLINICAL TRIALS

- A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV), Not Recruiting
- Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen, Not Recruiting
- Consent for Use of Stored Patient Specimens for Future Testing, Not Recruiting
- D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults, Not Recruiting
- Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection, Not Recruiting
- FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir, Not Recruiting
- High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART, Not Recruiting

- HIV Prevention and Care of Psychological Trauma in Vulnerable Rwandan Youth, Not Recruiting
- Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors, Not Recruiting
- Long-Term Data Collection From Participants in Adult AIDS Clinical Trials, Not Recruiting
- Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects, Not Recruiting
- Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment, Not Recruiting
- Prospective Observational Epidemiologic Study of Maraviroc's Safety, Not Recruiting
- Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women, Not Recruiting
- Rifaximin as a Modulator of Microbial Translocation and Immune Activation, Not Recruiting
- Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults, Not Recruiting
- Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults, Not Recruiting
- Safety and Efficacy of T Cell Genetic Immunotherapy for HIV, Not Recruiting
- Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults, Not Recruiting
- Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection, Not Recruiting
- Sevelamer for Reducing Endotoxemia and Immune Activation, Not Recruiting
- Stanford Universities: The Stanford HIV Aging Cohort, Not Recruiting
- Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients, Not Recruiting
- Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults, Not Recruiting
- Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults, Not Recruiting
- Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults, Not Recruiting
- Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults, Not Recruiting

## Publications

---

### PUBLICATIONS

- **Low Baseline CD4+ Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation.** *Clinical infectious diseases* Grant, P. M., Kitch, D., McComsey, G. A., Dube, M. P., Haubrich, R., Huang, J., Riddler, S., Tebas, P., Zolopa, A. R., Collier, A. C., Brown, T. T. 2013; 57 (10): 1483-1488
- **A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results** *JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES* Zolopa, A., Sax, P. E., deJesus, E., Mills, A., Cohen, C., Wohl, D., Gallant, J. E., Liu, H. C., Plummer, A., White, K. L., Cheng, A. K., Rhee, M. S., Szwarcberg, et al 2013; 63 (1): 96-100
- **Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms** *AIDS* Wood, B. R., Komarow, L., Zolopa, A. R., Finkelman, M. A., Powderly, W. G., Sax, P. E. 2013; 27 (6): 967-972
- **Patient monitoring and follow-up in lentiviral clinical trials** *JOURNAL OF GENE MEDICINE* McGarrity, G. J., Hoyah, G., Winemiller, A., Andre, K., Stein, D., Blick, G., Greenberg, R. N., Kinder, C., Zolopa, A., Binder-Scholl, G., Tebas, P., June, C. H., Humeau, et al 2013; 15 (2): 78-82
- **Elevated Interleukin 8 and T-Helper 1 and T-Helper 17 Cytokine Levels Prior to Antiretroviral Therapy in Participants Who Developed Immune Reconstitution Inflammatory Syndrome During ACTG A5164** *JOURNAL OF INFECTIOUS DISEASES*

Grant, P. M., Komarow, L., Lederman, M. M., Pahwa, S., Zolopa, A. R., Andersen, J., Asmuth, D. M., Devaraj, S., Pollard, R. B., Richterman, A., Kanthikeel, S., Sereti, I.  
2012; 206 (11): 1715-1723

● **When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now!** *Current HIV/AIDS reports*

Grant, P. M., Zolopa, A. R.  
2012; 9 (3): 251-258

● **Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks** *Lancet*

Sax, P. E., deJesus, E., Mills, A., Zolopa, A., Cohen, C., Wohl, D., Gallant, J. E., Liu, H. C., Zhong, L., Yale, K., White, K., Kearney, B. P., Szwarcberg, et al  
2012; 379 (9835): 2439-2448

● **Standardized Comparison of the Relative Impacts of HIV-1 Reverse Transcriptase (RT) Mutations on Nucleoside RT Inhibitor Susceptibility** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*

Melikian, G. L., Rhee, S., Taylor, J., Fessel, W. J., Kaufman, D., Towner, W., Troia-Cancio, P. V., Zolopa, A., Robbins, G. K., Kagan, R., Israelski, D., Shafer, R. W.  
2012; 56 (5): 2305-2313

● **Association of Low Level Viremia with Inflammation and Mortality in HIV-Infected Adults** *PLOS ONE*

Eastburn, A., Scherzer, R., Zolopa, A. R., Benson, C., Tracy, R., Do, T., Bacchetti, P., Shlipak, M., Grunfeld, C., Tien, P. C.  
2011; 6 (11)

● **Blood (1 -> 3)-beta-D-Glucan as a Diagnostic Test for HIV-Related Pneumocystis jirovecii Pneumonia** *CLINICAL INFECTIOUS DISEASES*

Sax, P. E., Komarow, L., Finkelman, M. A., Grant, P. M., Andersen, J., Scully, E., Powderly, W. G., Zolopa, A. R.  
2011; 53 (2): 197-202

● **Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis** *AIDS*

Bendavid, E., Grant, P., Talbot, A., Owens, D. K., Zolopa, A.  
2011; 25 (2): 211-220

● **Inflammation and Mortality in HIV-Infected Adults: Analysis of the FRAM Study Cohort** *JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*

Tien, P. C., Choi, A. I., Zolopa, A. R., Benson, C., Tracy, R., Scherzer, R., Bacchetti, P., Shlipak, M., Grunfeld, C.  
2010; 55 (3): 316-322

● **Concerns Regarding a Randomized Study of the Timing of Antiretroviral Therapy in Zimbabweans with AIDS and Acute Cryptococcal Meningitis** *CLINICAL INFECTIOUS DISEASES*

Grant, P. M., Aberg, J. A., Zolopa, A. R.  
2010; 51 (8): 984-985

● **HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*

Rhee, S., Taylor, J., Fessel, W. J., Kaufman, D., Towner, W., Troia, P., Ruane, P., Hellinger, J., Shirvani, V., Zolopa, A., Shafer, R. W.  
2010; 54 (10): 4253-4261

● **Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164** *HIV CLINICAL TRIALS*

Sax, P. E., Sloan, C. E., Schackman, B. R., Grant, P. M., Rong, J., Zolopa, A. R., Powderly, W., Losina, E., Freedberg, K. A.  
2010; 11 (5): 248-259

● **Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance** *CURRENT OPINION IN INVESTIGATIONAL DRUGS*

Grant, P. M., Zolopa, A. R.  
2010; 11 (8): 901-910

● **Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection** *PLOS ONE*

Grant, P. M., Komarow, L., Andersen, J., Sereti, I., Pahwa, S., Lederman, M. M., Eron, J., Sanne, I., Powderly, W., Hogg, E., Suckow, C., Zolopa, A.  
2010; 5 (7)

● **Predicting Tipranavir and Darunavir Resistance Using Genotypic, Phenotypic, and Virtual Phenotypic Resistance Patterns: an Independent Cohort Analysis of Clinical Isolates Highly Resistant to All Other Protease Inhibitors** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*

Talbot, A., Grant, P., Taylor, J., Baril, J., Liu, T. F., Charest, H., Brenner, B., Roger, M., Shafer, R., Cantin, R., Zolopa, A.  
2010; 54 (6): 2473-2479

• **International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*

Grant, P. M., Taylor, J., Nevins, A. B., Calvez, V., Marcellin, A., Wirden, M., Zolopa, A. R.  
2010; 54 (4): 1520-1525

• **Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical Trial** *JOURNAL OF INFECTIOUS DISEASES*

Zolopa, A. R., Berger, D. S., Lampiris, H., Zhong, L., Chuck, S. L., Enejosa, J. V., Kearney, B. P., Cheng, A. K.  
2010; 201 (6): 814-822

• **Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets** *17th International HIV Drug Resistance Workshop*

Assoumou, L., Cozzi-Lepri, A., Brun-Vezinet, F., DeGruttola, V., Kuritzkes, D. R., Phillips, A., Zolopa, A., Miller, V., Flandre, P., Costagliola, D.  
LIPPINCOTT WILLIAMS & WILKINS.2010: 365-71

• **Association of HIV Infection, Demographic and Cardiovascular Risk Factors With All-Cause Mortality in the Recent HAART Era** *JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*

Cockerham, L., Scherzer, R., Zolopa, A., Rimland, D., Lewis, C. E., Bacchetti, P., Grunfeld, C., Shlipak, M., Tien, P. C.  
2010; 53 (1): 102-106

• **The evolution of HIV treatment guidelines: Current state-of-the-art of ART** *ANTIVIRAL RESEARCH*

Zolopa, A. R.  
2010; 85 (1): 241-244

• **Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life** *JOURNAL OF CLINICAL VIROLOGY*

Grant, P. M., Palmer, S., Bendavid, E., Talbot, A., Slamowitz, D. C., Cain, P., Kobayashi, S. S., Balamane, M., Zolopa, A. R.  
2009; 46 (4): 305-308

• **Nonpolymorphic Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Treatment-Selected Mutations** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*

Shahriar, R., Rhee, S., Liu, T. F., Fessel, W. J., Scarsella, A., Towner, W., Holmes, S. P., Zolopa, A. R., Shafer, R. W.  
2009; 53 (11): 4869-4878

• **The use of resistance testing in the management of HIV-1-infected patients** *CURRENT OPINION IN HIV AND AIDS*

Grant, P. M., Zolopa, A. R.  
2009; 4 (6): 474-480

• **Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial** *PLOS ONE*

Zolopa, A. R., Andersen, J., Komarow, L., Sanne, I., Sanchez, A., Hogg, E., Suckow, C., Powderly, W.  
2009; 4 (5)

• **Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose.** *Current HIV/AIDS reports*

Grant, P., Zolopa, A.  
2009; 6 (2): 63-67

• **Maintaining Reduced Viral Fitness and CD4 Response in HIV-Infected Patients with Viremia Receiving a Boosted Protease Inhibitor** *CLINICAL INFECTIOUS DISEASES*

Grant, P., Taylor, J., Cain, P., Short, W., Gallant, J., Farthing, C., Thal, G., Coakley, E., Zolopa, A.  
2009; 48 (5): 680-682

• **Hepatotoxicity and Gastrointestinal Intolerance When Healthy Volunteers Taking Rifampin Add Twice-Daily Atazanavir and Ritonavir** *15th Conference on Retroviruses and Opportunistic Infections*

Haas, D. W., Koletar, S. L., Laughlin, L., Kendall, M. A., Suckow, C., Gerber, J. G., Zolopa, A. R., Bertz, R., Child, M. J., Hosey, L., Alston-Smith, B., Acosta, E. P.  
LIPPINCOTT WILLIAMS & WILKINS.2009: 290-93

- **Safety and Efficacy of Enfuvirtide in Combination with Darunavir-Ritonavir and an Optimized Background Regimen in Treatment-Experienced Human Immunodeficiency Virus-Infected Patients: the Below the Level of Quantification Study** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*  
DeJesus, E., Gottlieb, M. S., Gathe, J. C., Greenberg, M. L., Guittari, C. J., Zolopa, A. R.  
2008; 52 (12): 4315-4319
- **Virologic Response to Lopinavir-Ritonavir-Based Antiretroviral Regimens in a Multicenter International Clinical Cohort: Comparison of Genotypic Interpretation Scores** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*  
Grant, P., Wong, E. C., Rode, R., Shafer, R., De Luca, A., Nadler, J., Hawkins, T., Cohen, C., Harrington, R., Kempf, D., Zolopa, A.  
2008; 52 (11): 4050-4056
- **Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial** *AMERICAN JOURNAL OF CLINICAL NUTRITION*  
Sattler, F. R., Rajacic, N., Mulligan, K., Yarasheski, K. E., Koletar, S. L., Zolopa, A., Alston, B., Zackin, S. R., Bistrian, B.  
2008; 88 (5): 1313-1321
- **Initiatives for developing and comparing genotype interpretation systems: External validation of existing systems for didanosine against virological response** *JOURNAL OF INFECTIOUS DISEASES*  
Assoumou, L., Brun-Vezinet, F., Cozzi-Lepri, A., Kuritzkes, D., Phillips, A., Zolopa, A., DeGruttola, V., Miller, V., Costagliola, D.  
2008; 198 (4): 470-480
- **Integrase inhibitors: a clinical review of raltegravir and elvitegravir.** *Journal of HIV therapy*  
Grant, P., Zolopa, A.  
2008; 13 (2): 36-39
- **Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*  
Acosta, E. P., Kendall, M. A., Gerber, J. G., Alston-Smith, B., Koletar, S. L., Zolopa, A. R., Agarwala, S., Child, M., Bertz, R., Hosey, L., Haas, D. W.  
2007; 51 (9): 3104-3110
- **Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment experienced patients: AIDS clinical trials group 5211** *16th International AIDS Conference*  
Gulick, R. M., Su, Z., Flexner, C., Hughes, M. D., Skolnik, P. R., Wilkin, T. J., Gross, R., Krambrink, A., Coakley, E., Greaves, W. L., Zolopa, A., Reichman, R., Godfrey, et al  
UNIV CHICAGO PRESS.2007: 304-12
- **A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)** *JOURNAL OF INFECTIOUS DISEASES*  
Kilby, J. M., Bucy, R. P., Mildvan, D., Fischl, M., Santana-Bagur, J., Lennox, J., Pilcher, C., Zolopa, A., Lawrence, J., Pollard, R. B., El Habib, R., Sahner, D., Fox, et al  
2006; 194 (12): 1672-1676
- **N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure** *AIDS RESEARCH AND HUMAN RETROVIRUSES*  
Mitsuya, Y., Winters, M. A., Fessel, W. J., Rhee, S., Hurley, L., Horberg, M., Schiffer, C. A., Zolopa, A. R., Shafer, R. W.  
2006; 22 (12): 1300-1305
- **Incorporating drug-resistance measurements into the clinical management of HIV-1 infection** *Symposium on Bridging Generations Toward an Understanding of Infectious Disease Pathogenesis*  
Zolopa, A. R.  
UNIV CHICAGO PRESS.2006: S59-S64
- **The study of fat redistribution and metabolic change in HIV infection (FRAM): Methods, design, and sample characteristics** *AMERICAN JOURNAL OF EPIDEMIOLOGY*  
Tien, P. C., Benson, C., Zolopa, A. R., Sidney, S., Osmond, D., Grunfeld, C.  
2006; 163 (9): 860-869
- **The effect of diagnosis with HIV infection on health-related quality of life** *QUALITY OF LIFE RESEARCH*  
Honiden, S., Sundaram, V., Nease, R. F., Holodniy, M., Lazzeroni, L. C., Zolopa, A., Owens, D. K.  
2006; 15 (1): 69-82
- **Case files from Stanford University Medical Center: the initial presentation of HIV-1 infection--where public and personal health meet.** *MedGenMed : Medscape general medicine*

- Liu, M., Holodniy, M., Zolopa, A. R., Shafer, R. W.  
2006; 8 (1): 24-?
- **HIV-1 protease and reverse-transcriptase mutations: Correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance** *13th International AIDS Conference*  
Rhee, S. Y., Fessel, W. J., Zolopa, A. R., Hurley, L., Liu, T., Taylor, J., Nguyen, D. P., Slome, S., Klein, D., Horberg, M., Flamm, J., Follansbee, S., Schapiro, et al  
UNIV CHICAGO PRESS.2005: 456-65
  - **Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers** *42nd Annual Meeting of the Infectious-Diseases-Society-of-America*  
Glesby, M. J., Aberg, J. A., Kendall, M. A., Fichtenbaum, C. J., Hafner, R., Hall, S., Grosskopf, N., Zolopa, A. R., Gerber, J. G.  
NATURE PUBLISHING GROUP.2005: 143-53
  - **Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection** *CLINICAL INFECTIOUS DISEASES*  
Campbell, T. B., Shulman, N. S., Johnson, S. C., Zolopa, A. R., Young, R. K., Bushman, L., Fletcher, C. V., Lanier, E. R., Merigan, T. C., Kuritzkes, D. R.  
2005; 41 (2): 236-242
  - **Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: An international comparison (The GUESS Study)** *CLINICAL INFECTIOUS DISEASES*  
Zolopa, A. R., Lazzeroni, L. C., Rinehart, A., Vezinet, F. B., Clavel, F., Collier, A., Conway, B., Gulick, R. M., Holodniy, M., Perno, C. F., Shafer, R. W., Richman, D. D., Wainberg, et al  
2005; 41 (1): 92-99
  - **Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine** *12th International HIV Drug Resistance Workshop*  
Lecossier, D., Shulman, N. S., Morand-Joubert, L., Shafer, R. W., Joly, V., Zolopa, A. R., Clavel, F., Hance, A. J.  
LIPPINCOTT WILLIAMS & WILKINS.2005: 37-42
  - **Prevalence of antiretroviral drug resistance in the HIV-1-infected urban indigent population in San Francisco: a representative study** *INTERNATIONAL JOURNAL OF STD & AIDS*  
Holodniy, M., Charlebois, E. D., Bangsberg, D. R., Zolopa, A. R., Schulte, M., Moss, A. R.  
2004; 15 (8): 543-551
  - **Clinically validated genotype analysis: guiding principles and statistical concerns** *ANTIVIRAL THERAPY*  
Brun-Vezinet, F., Costagliolo, D., Khaled, M. A., Calvez, V., Clavel, F., Clotet, B., Haubrich, R., Kemp, D., King, M., Kuritzkes, D., Lanier, R., Miller, M., Miller, et al  
2004; 9 (4): 465-478
  - **High levels of adherence do not prevent accumulation of HIV drug resistance mutations** *AIDS*  
Bangsberg, D. R., Charlebois, E. D., Grant, R. M., Holodniy, M., Deeks, S. G., Perry, S., Conroy, K. N., Clark, R., Guzman, D., Zolopa, A., Moss, A.  
2003; 17 (13): 1925-1932
  - **Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation** *11th International Workshop on HIV Drug Resistance and Treatment Strategies*  
Gonzales, M. J., Delwart, E., Rhee, S. Y., Tsui, R., Zolopa, A. R., Taylor, J., Shafer, R. W.  
UNIV CHICAGO PRESS.2003: 397-405
  - **Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors** *AIDS*  
Gonzales, M. J., Wu, T. D., Taylor, J., Belitskaya, F., Kantor, R., Israelski, D., Chou, S., Zolopa, A. R., Fessel, W. J., Shafer, R. W.  
2003; 17 (6): 791-799
  - **Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments** *JOURNAL OF VIROLOGY*  
Wu, T. D., Schiffer, C. A., Gonzales, M. J., Taylor, J., Kantor, R., Chou, S. W., Israelski, D., Zolopa, A. R., Fessel, W. J., Shafer, R. W.  
2003; 77 (8): 4836-4847
  - **Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*  
Shulman, N., Zolopa, A., Havlir, D., Hsu, A., Renz, C., Boller, S., Jiang, P., Rode, R., Gallant, J., Race, E., Kempf, D. J., Sun, E.  
2002; 46 (12): 3907-3916

- **Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients** *1st IAS Conference on HIV Pathogenesis and Treatment*  
Shulman, N. S., Hughes, M. D., Winters, M. A., Shafer, R. W., Zolopa, A. R., Hellmann, N. S., Bates, M., Whitcomb, J. M., Katzenstein, D. A.  
LIPPINCOTT WILLIAMS & WILKINS.2002: 121–27
- **Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*  
Kantor, R., Fessel, W. J., Zolopa, A. R., Israelski, D., Shulman, N., Montoya, J. G., Harbour, M., Schapiro, J. M., Shafer, R. W.  
2002; 46 (4): 1086-1092
- **Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART)** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*  
Morris, M. K., Katzenstein, D. A., Israelski, D., Zolopa, A., Hendry, R. M., Hanson, C. V.  
2001; 28 (5): 405-415
- **HIV drug resistance testing: an update for the clinician.** *AIDS clinical care*  
RICE, H. L., Zolopa, A. R.  
2001; 13 (10): 89-?
- **Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*  
Shulman, N. S., Machekano, R. A., Shafer, R. W., Winters, M. A., Zolopa, A. R., Liou, S. H., Hughes, M., Katzenstein, D. A.  
2001; 27 (4): 377-380
- **Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy** *AIDS*  
Shulman, N., Zolopa, A. R., Passaro, D., Shafer, R. W., Huang, W., KATZENSTEIN, D., Israelski, D. M., Hellmann, N., Petropoulos, C., Whitcomb, J.  
2001; 15 (9): 1125-1132
- **Non-adherence to highly active antiretroviral therapy predicts progression to AIDS** *AIDS*  
Bangsberg, D. R., Perry, S., Charlebois, E. D., Clark, R. A., Roberston, M., Zolopa, A. R., Moss, A.  
2001; 15 (9): 1181-1183
- **High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients** *JOURNAL OF CLINICAL MICROBIOLOGY*  
Shafer, R. W., Hertogs, K., Zolopa, A. R., Warford, A., Bloor, S., Betts, B. J., Merigan, T. C., Harrigan, R., Larder, B. A.  
2001; 39 (4): 1522-1529
- **Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8(+) T cells** *AIDS RESEARCH AND HUMAN RETROVIRUSES*  
Gray, C. M., Lawrence, J., Ranheim, E. A., Vierra, M., Zupancic, M., Winters, M., Altman, J., Montoya, J., Zolopa, A., Schapiro, J., Haase, A. T., Merigan, T. C.  
2000; 16 (14): 1357-1369
- **Adherence to isoniazid prophylaxis in the homeless - A randomized controlled trial** *ARCHIVES OF INTERNAL MEDICINE*  
Tulsky, J. P., Pilote, L., Hahn, J. A., Zolopa, A., Burke, M., Chesney, M., Moss, A. R.  
2000; 160 (5): 697-702
- **Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population** *AIDS*  
Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Zolopa, A. R., Holodniy, M., Sheiner, L., Bamberger, J. D., Chesney, M. A., Moss, A.  
2000; 14 (4): 357-366
- **Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*  
Shulman, N. S., Zolopa, A. R., Passaro, D. J., Murlidharan, U., Israelski, D. M., Brosgart, C. L., Miller, M. D., Van Doren, S., Shafer, R. W., Katzenstein, D. A.  
2000; 23 (3): 221-226
- **The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan** *ANTIVIRAL THERAPY*  
DeGruttola, V., Dix, L., D'Aquila, R., Holder, D., Phillips, A., Ait-Khaled, M., Baxter, J., Clevenbergh, P., Hammer, S., Harrigan, R., KATZENSTEIN, D., Lanier, R., Miller, et al  
2000; 5 (1): 41-48

- **HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed** *ANNALS OF INTERNAL MEDICINE*  
Zolopa, A. R., Shafer, R. W., Warford, A., Montoya, J. G., Hsu, P., KATZENSTEIN, D., Merigan, T. C., Efron, B.  
1999; 131 (11): 813-?
- **Invasive fungal sinusitis due to *Scedosporium apiospermum* in a patient with AIDS** *CLINICAL INFECTIOUS DISEASES*  
Eckburg, P. B., Zolopa, A. R., Montoya, J. G.  
1999; 29 (1): 212-213
- **Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons** *5th Conference on Retroviruses and Opportunistic Infections*  
Lawrence, J., Schapiro, J., Winters, M., Montoya, J., Zolopa, A., Pesano, R., Efron, B., Winslow, D., Merigan, T. C.  
UNIV CHICAGO PRESS.1999: 1356-64
- **Association between time homeless and perceived health status among the homeless in San Francisco** *JOURNAL OF COMMUNITY HEALTH*  
White, M. C., Tulsky, J. P., Dawson, C., Zolopa, A. R., Moss, A. R.  
1997; 22 (4): 271-282
- **PREVALENCE OF MEASLES ANTIBODIES IN ADULTS WITH HIV-INFECTION - POSSIBLE RISK-FACTORS OF MEASLES SERONEGATIVITY AIDS**  
Kemper, C. A., Zolopa, A. R., Hamilton, J. R., Fenstersheib, M., Bhatia, G., Deresinski, S. C.  
1992; 6 (11): 1321-1325